PASG
Passage Bio Inc
1 day chart
About PASG
Passage Bio, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes a AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (B-gal), for GM1. Its second product candidate, PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN), for FTD caused by progranulin deficiency (FTD-GRN). The Company has two programs in the research stage: PBAL05 for amyotrophic lateral sclerosis (ALS), and an unnamed program for Huntington’s disease. PBAL05 is targeting patients with ALS who have a gain-of-function mutation in the C9orf72 gene. It also has an exploratory research program for larger non-monogenic indications, which is focused on temporal lobe epilepsy (TLE).
Buy US stocks in Australia starting with PASG. Open an account and start investing today!
$52.93M
-
0.00%
10
$1.05
$0.96
$0.00
$2.89
$0.95
PASG FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in PASG
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.